Wednesday, December 23, 2009
With Central Labs coming up in February, we've started an interview series with some of the speakers we're looking forward to in February.
Our second podcast is with Craig Lipset, Central Labs West conference chair. During this podcast, they answer the following questions:
-What are Craig's passion points?
-Why does the Central Labs West conference resonate with him?
-He discusses how industry continues to explore novel imaging techniques in the context of their early phase development programs.
-He discusses some of the standardization taking place in the industry.
-Lipset looks at what he sees coming in the future for this industry.
Saturday, January 31, 2009
"All simple diseases have been solved", says Stoffels, in the context of describing the need for industry to look beyond their own walls for answers.
I agree with the conclusion -- pharma must partner to solve their current challenges. Partner with academia, and even with others in industry.
But is it true that we have solved all of the simple diseases? Or will history prove that we are still at the tip of a much bigger iceberg?
Hood does a great job of breaking down the impact of a faltering economy upon an already strained system. Pharma is axing researchers. Biotechs are at great risk for bankruptcy. Venture capitalists are retreating. Government is not prepared to pick up the slack. Private foundations lack the capital or scope.
Is a new role for the public sector needed to ensure that the current 10-15 years to develop a new therapy does not get longer instead of shorter?
Wednesday, January 21, 2009
Well, the truth of course is that this is a cycle and the research and sales halves of the pharmaco are dependent on one another. The commercial organization needs new products to sell and generate revenue. The research organization needs a percent of the revenue from sales to re-invest in new R&D.
So there is an up-side for clinical development when pharma use direct-to-consumer advertising as a tool to increase sales.
But there is certainly a downside. And Ken Getz from Tufts does his usual outstanding job describing the implications of public perception on clinical research. How have we contributed to the public's lack of understanding the risk of medicines and clinical trials? What role has DTC advertising played in painting the image of high-benefit / no-risk?
It may be a moot point -- if studies continue to mount showing DTC ads are "losing their punch" then the fate of DTC will be decided by the market.
This month Forbes notes an interesting up-side for clinical development coming out of a down economy – individuals feeling a pinch in their wallets increasingly interested in participating in paid studies.
Studies that pay for enrollment are generally for health volunteers, and are typically performed at dedicated Phase I / clinical research units. Such units often have databases of subjects in their catchment area – including their “professional patients”.
But healthy volunteer studies, as with much of clinical research, was seeing a trend moving outside of the